Eisai Co Ltd 2018 Integrated Report
The report presents the company’s human health care philosophy, placing patient satisfaction before financial results. It reports consolidated FY2017 revenue of ¥600.1 billion and describes broad partnerships to expand innovation and access to medicines. ESG highlights include free DEC tablet provision for lymphatic filariasis, an accepted SBTi commitment, a B CDP Climate Change score, and joining the UN Global Compact.
Company: Eisai Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2018
Type: Integrated Report
Pages: 99
Back to company
Eisai Co Ltd
Integrated Report
The report presents the company’s human health care philosophy, placing patient satisfaction before financial results. It reports consolidated FY2017 revenue of ¥600.1 billion and describes broad partnerships to expand innovation and access to medicines. ESG highlights include free DEC tablet provision for lymphatic filariasis, an accepted SBTi commitment, a B CDP Climate Change score, and joining the UN Global Compact.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees